Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Walter Albrecht

Showing results (11-20 of 30) with videos related to

Pageof 3
Sort By:
Journal of Clinical Medicine|September 23, 2022
Increased Respiratory Drive after Prolonged Isoflurane Sedation: A Retrospective Cohort StudyLukas Martin Müller-Wirtz, Dustin Grimm, Frederic Walter Albrecht, et al.
European Urology|June 3, 2011
EAU guidelines on testicular cancer: 2011 updatePeter Albers, Walter Albrecht, Ferran Algaba, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 2, 2004
Is baseline quality of life useful for predicting survival with hormone-refractory prostate cancer? A pooled analysis of three studies of the European Organisation for Research and Treatment of Cancer Genitourinary GroupLaurence Collette, George van Andel, Andrew Bottomley, et al.
European Urology|August 30, 2005
Guidelines on testicular cancerPeter Albers, Walter Albrecht, Ferran Algaba, et al.
Anticancer Research|July 2, 2010
Proposal for a standardized PSA doubling-time calculationAnton Ponholzer, Nikolaus Popper, Felix Breitenecker, et al.
The Journal of Urology|May 19, 2007
A prospective, open label, randomized phase II trial of weekly docetaxel versus weekly vinorelbine as first line chemotherapy in patients with androgen independent prostate cancerMichael Krainer, Sandra Tomek, Katarzyna Elandt, et al.
European Urology|August 23, 2015
Guidelines on Testicular Cancer: 2015 UpdatePeter Albers, Walter Albrecht, Ferran Algaba, et al.
European Urology|October 24, 2003
Intermittent maximal androgen blockade in patients with metastatic prostate cancer: an EORTC feasibility studyWalter Albrecht, Laurence Collette, Cesare Fava, et al.
Urologic Oncology|February 19, 2017
Prognostic role of N-cadherin expression in patients with non-muscle-invasive bladder cancerMohammad Abufaraj, Shahrokh F Shariat, Andrea Haitel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2006
Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891Urs E Studer, Peter Whelan, Walter Albrecht, et al.
Pageof 3

Showing results (11-20 of 30) with videos related to

Sort By:
Pageof 3
Journal of Clinical Medicine|September 23, 2022
Increased Respiratory Drive after Prolonged Isoflurane Sedation: A Retrospective Cohort StudyLukas Martin Müller-Wirtz, Dustin Grimm, Frederic Walter Albrecht, et al.
European Urology|June 3, 2011
EAU guidelines on testicular cancer: 2011 updatePeter Albers, Walter Albrecht, Ferran Algaba, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 2, 2004
Is baseline quality of life useful for predicting survival with hormone-refractory prostate cancer? A pooled analysis of three studies of the European Organisation for Research and Treatment of Cancer Genitourinary GroupLaurence Collette, George van Andel, Andrew Bottomley, et al.
European Urology|August 30, 2005
Guidelines on testicular cancerPeter Albers, Walter Albrecht, Ferran Algaba, et al.
Anticancer Research|July 2, 2010
Proposal for a standardized PSA doubling-time calculationAnton Ponholzer, Nikolaus Popper, Felix Breitenecker, et al.
The Journal of Urology|May 19, 2007
A prospective, open label, randomized phase II trial of weekly docetaxel versus weekly vinorelbine as first line chemotherapy in patients with androgen independent prostate cancerMichael Krainer, Sandra Tomek, Katarzyna Elandt, et al.
European Urology|August 23, 2015
Guidelines on Testicular Cancer: 2015 UpdatePeter Albers, Walter Albrecht, Ferran Algaba, et al.
European Urology|October 24, 2003
Intermittent maximal androgen blockade in patients with metastatic prostate cancer: an EORTC feasibility studyWalter Albrecht, Laurence Collette, Cesare Fava, et al.
Urologic Oncology|February 19, 2017
Prognostic role of N-cadherin expression in patients with non-muscle-invasive bladder cancerMohammad Abufaraj, Shahrokh F Shariat, Andrea Haitel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2006
Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891Urs E Studer, Peter Whelan, Walter Albrecht, et al.
Pageof 3